直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

PTAB Statistics for Final Written Decisions Issued in February 2025

April 4, 2025

Authored and Edited by Daniel F. Klodowski; Deena Kablaoui Lanier; Nicholas A. Eitsert; Elliot C. Cook

In February, a relatively difficult month for patent owners, the PTAB cancelled 451 (79.96%) instituted claims across 37 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit.  A significant contributor to the large number of cancelled claims in February was the Board’s Final Written Decision in a set of three consolidated PGRs (Simpson Strong-Tie Co. v. Columbia Insurance Co., Nos. PGR2023-00047, -00048, and -00049), which collectively addressed the patentability of 105 instituted claims, resulting in 103 cancelled claims and 2 claims surviving. In total, 83 (14.72%) instituted claims survived in February FWDs, and patent owners conceded 30 (5.32%) instituted claims through motions to amend or disclaimer (in cases reaching a final decision).  For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is slightly below 74%.

On a per-case basis, no instituted or substitute claims survived in 27 (72.97%) decisions, all instituted claims survived in 5 (13.51%) decisions, and 5 (13.51%) decisions had a mixed outcome in which at least one instituted or substitute claim survived and at least one instituted claim was cancelled. 

Turning to motions to amend that were addressed on the merits in a Final Written Decision, the PTAB has cumulatively granted 662 (15.53%) proposed substitute claims while denying 3,601 (84.47%) proposed substitute claims through February 28, 2025. 

Patentees have had slightly more success with motions to amend in PGRs.  The PTAB has cumulatively granted 69 (20.60%) proposed substitute claims in PGR motions to amend while denying 266 (79.40%) proposed substitute claims.

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through February 28, 2025, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through February 28, 2025, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through February 28, 2025, are available here on the At the PTAB blog. 

Various other PTAB metrics collected and generated by Finnegan are reserved for the use of Finnegan and its clients.  Stay tuned to the At the PTAB Blog for the latest updates, analysis, and statistics on all aspects of PTAB practice.  Subscribe to receive notifications of new posts via email.

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Deena Kablaoui Lanier
Associate
Washington, DC
+1 202 408 4115
Email
Nicholas A. Eitsert
Associate
Washington, DC
+1 202 408 4157
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

Conference

17th Summit on Biosimilars & Innovator Biologics

June 2-3, 2026

New York

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

Articles

Colorado Replaces Landmark AI Act: An Overview of the New SB 26-189 Framework

May 26, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP